Nice, France

Patrick Auberger

USPTO Granted Patents = 3 

 

 

Average Co-Inventor Count = 4.3

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2014-2015

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Patrick Auberger

Introduction

Patrick Auberger is a notable inventor based in Nice, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of cancer treatments. With a total of three patents to his name, Auberger's work focuses on innovative therapeutic methods and compositions.

Latest Patents

Auberger's latest patents include groundbreaking research on Acadesine derivatives. These derivatives are described as potential drugs for the treatment of cancer, specifically chronic myeloid leukemia. His patents detail not only the therapeutic uses of these derivatives but also methods for synthesizing them. Additionally, he has explored the use of Simalikalactone E as an anticancer agent, emphasizing its potential in preventing and treating various cancers.

Career Highlights

Throughout his career, Auberger has been associated with prestigious institutions such as Université Nice Sophia Antipolis and the Institut National de la Santé et de la Recherche Médicale. His work has garnered attention for its innovative approach to cancer treatment, showcasing his commitment to advancing medical science.

Collaborations

Auberger has collaborated with notable colleagues, including Guillaume Robert and Rachid Benhida. These partnerships have contributed to the success of his research and the development of his patents.

Conclusion

Patrick Auberger's contributions to the field of cancer treatment through his innovative patents highlight his role as a leading inventor. His work continues to inspire advancements in medical research and therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…